With respect to treatments, standards of care must include SGLT2 inhibitors combined with RAAS blockers for heart failure stages B, C and D and GLP-1 receptor agonist with metformin for atherosclerotic cardiovascular disease or peripheral artery disease. Here, SLC5A2 is linked to peripheral arterial disease.